Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.
复制标题
DOI：
10.2147/dmso.s154602
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Pettus J
中科院分区：
文献类型：
--
作者：
Cavaiola TS;Pettus J
作为第一个证明降糖药物可降低 2 型糖尿病 (T2DM) 患者心血管事件风险的降糖药物心血管 (CV) 结局试验，EMPAgliflozin 去除过量葡萄糖：2 型糖尿病患者心血管结局事件试验 (EMPA-REG OUTCOME®) 试验研究了钠葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂empagliflozin 引起了医疗保健专业人员的极大兴趣。另一种 SGLT2 抑制剂卡格列净的 CV 结果数据最近已在 CANagliflozin 心血管评估研究 (CANVAS) 计划中发表，以及来自回顾性现实研究钠-葡萄糖协同转运蛋白 2 抑制剂新用户心血管结果比较有效性 (CVD-REAL) 的 CV 数据，该研究将 SGLT2 抑制剂与其他类别的降糖药物进行了比较。本综述讨论了这三项研究的结果，并重点关注 EMPA-REG 结果，探讨了 SGLT2 抑制剂降低 T2DM 患者心血管风险的可能机制。
As the first cardiovascular (CV) outcome trial of a glucose-lowering agent to demonstrate a reduction in the risk of CV events in patients with type 2 diabetes mellitus (T2DM), the EMPAgliflozin Removal of Excess Glucose: Cardiovascular OUTCOME Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME®) trial, which investigated the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, has generated great interest among health care professionals. CV outcomes data for another SGLT2 inhibitor, canagliflozin, have been published recently in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program, as have CV data from the retrospective real-world study Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors (CVD-REAL), which compared SGLT2 inhibitors with other classes of glucose-lowering drugs. This review discusses the results of these three studies and, with a focus on EMPA-REG OUTCOME, examines the possible mechanisms by which SGLT2 inhibitors may reduce CV risk in patients with T2DM.